keyword
MENU ▼
Read by QxMD icon Read
search

recurrent malaria

keyword
https://www.readbyqxmd.com/read/29345221/therapeutic-response-to-dihydroartemisinin-piperaquine-for-p-falciparum-and-p-vivax-nine-years-after-its-introduction-in-southern-papua-indonesia
#1
Jeanne Rini Poespoprodjo, Enny Kenangalem, Johny Wafom, Freis Chandrawati, Agatha M Puspitasari, Benedikt Ley, Leily Trianti, Zoé Korten, Asik Surya, Din Syafruddin, Nicholas M Anstey, Jutta Marfurt, Rintis Noviyanti, Ric N Price
Dihydroartemisinin-piperaquine (DHP) has been the first-line treatment of uncomplicated malaria due to both Plasmodium falciparum and Plasmodium vivax infections in Papua, Indonesia, since March 2006. The efficacy of DHP was reassessed to determine whether there had been any decline following almost a decade of its extensive use. An open-label drug efficacy study of DHP for uncomplicated P. falciparum and P. vivax malaria was carried out between March 2015 and April 2016 in Timika, Papua, Indonesia. Patients with uncomplicated malaria were administered supervised DHP tablets once daily for 3 days...
January 15, 2018: American Journal of Tropical Medicine and Hygiene
https://www.readbyqxmd.com/read/29313573/p-vivax-malaria-presenting-as-thrombotic-microangiopathy
#2
Dharmendra Bhadauria, Harsh Vardhan, Anupma Kaul, Raj Kumar Sharma, Amit Gupta, Narayan Prasad, Manoj Jain
Introduction: Acute kidney injury (AKI) is reported to occur in patients with falciparum malaria but not uncommon with vivax malaria. AKI, anemia, thrombocytopenia and jaundice is a recurrent finding in severe malaria and can mimic as thrombotic microangiopathy (TMA). Relationship of malaria with TMA is unclear till date however evidences suggest their association. Methods & Material: We reviewed our electronic database to evaluate relationship of malaria with TMA, of cases of malaria, jaundice and AKI...
September 2017: Journal of the Association of Physicians of India
https://www.readbyqxmd.com/read/29281988/intravenous-artesunate-plus-artemisnin-based-combination-therapy-act-or-intravenous-quinine-plus-act-for-treatment-of-severe-malaria-in-ugandan-children-a-randomized-controlled-clinical-trial
#3
Pauline Byakika-Kibwika, Jane Achan, Mohammed Lamorde, Carine Karera-Gonahasa, Agnes N Kiragga, Harriet Mayanja-Kizza, Noah Kiwanuka, Sam Nsobya, Ambrose O Talisuna, Concepta Merry
BACKGROUND: Severe malaria is a medical emergency associated with high mortality. Adequate treatment requires initial parenteral therapy for fast parasite clearance followed by longer acting oral antimalarial drugs for cure and prevention of recrudescence. METHODS: In a randomized controlled clinical trial, we evaluated the 42-day parasitological outcomes of severe malaria treatment with intravenous artesunate (AS) or intravenous quinine (QNN) followed by oral artemisinin based combination therapy (ACT) in children living in a high malaria transmission setting in Eastern Uganda...
December 28, 2017: BMC Infectious Diseases
https://www.readbyqxmd.com/read/29237461/systematic-literature-review-and-meta-analysis-of-the-efficacy-of-artemisinin-based-and-quinine-based-treatments-for-uncomplicated-falciparum-malaria-in-pregnancy-methodological-challenges
#4
Makoto Saito, Mary Ellen Gilder, François Nosten, Rose McGready, Philippe J Guérin
BACKGROUND: There is no agreed standard method to assess the efficacy of anti-malarials for uncomplicated falciparum in pregnancy despite an increased risk of adverse outcomes for the mother and the fetus. The aim of this review is to present the currently available evidence from both observational and interventional cohort studies on anti-malarial efficacy in pregnancy and summarize the variability of assessment and reporting found in the review process. METHODS: Efficacy methodology and assessment of artemisinin-based treatments (ABT) and quinine-based treatments (QBT) were reviewed systematically using seven databases and two clinical trial registries (protocol registration-PROSPERO: CRD42017054808)...
December 13, 2017: Malaria Journal
https://www.readbyqxmd.com/read/29216842/a-clinical-tool-to-predict-plasmodium-vivax-recurrence-in-malaysia
#5
Norliza Mat Ariffin, Farida Islahudin, Endang Kumolosasi, Mohd Makmor-Bakry
BACKGROUND: Recurrence rates of Plasmodium vivax infections differ across various geographic regions. Interestingly, South-East Asia and the Asia-Pacific region are documented to exhibit the most frequent recurrence incidences. Identifying patients at a higher risk for recurrences gives valuable information in strengthening the efforts to control P. vivax infections. The aim of the study was to develop a tool to identify P. vivax- infected patients that are at a higher risk of recurrence in Malaysia...
December 8, 2017: BMC Infectious Diseases
https://www.readbyqxmd.com/read/29141762/efficacy-of-artemether-lumefantrine-for-uncomplicated-plasmodium-falciparum-malaria-in-cruzeiro-do-sul-brazil-2016
#6
Megumi Itoh, Suiane Negreiros do Valle, Sâmela Farias, Thayna Maria Holanda de Souza, Giselle Maria Rachid Viana, Naomi Lucchi, Stella Chenet, Paola Marchesini, Marinete Póvoa, Ana Carolina Faria E Silva Santelli, Alexandre Macedo de Oliveira
We evaluated the therapeutic efficacy of artemether-lumefantrine (AL) fixed-dose combination to treat uncomplicated Plasmodium falciparum malaria in Cruzeiro do Sul, Acre State, in the Amazon region of Brazil. Between December 2015 and May 2016, we enrolled 79 patients, 5-79 years old with fever or history of fever in the previous 48 hours and P. falciparum monoinfection confirmed by microscopy. Attempts were made to provide direct observation or phone reminders for all six doses of AL, and patients were followed-up for 28 days...
November 6, 2017: American Journal of Tropical Medicine and Hygiene
https://www.readbyqxmd.com/read/29141719/chloroquine-primaquine-versus-chloroquine-alone-to-treat-vivax-malaria-in-afghanistan-an-open-randomized-superiority-trial
#7
Ghulam Rahim Awab, Mallika Imwong, Germana Bancone, Atthanee Jeeyapant, Nicholas P J Day, Nicholas J White, Charles J Woodrow
Afghanistan's national guidelines recommend primaquine (PQ) for radical treatment of Plasmodium vivax malaria, but this is rarely implemented because of concerns over potential hemolysis in patients who have G6PD deficiency. Between August 2009 and February 2014, we conducted an open-label, randomized controlled trial of chloroquine (CQ) alone versus chloroquine plus primaquine (0.25 mg base/kg/day for 14 days) (CQ+PQ) in patients aged 6 months and older with microscopy confirmed P. vivax infection. In the CQ+PQ group, G6PD deficiency was excluded by fluorescent spot testing...
October 30, 2017: American Journal of Tropical Medicine and Hygiene
https://www.readbyqxmd.com/read/29115961/plasmodium-falciparum-variant-erythrocyte-surface-antigens-a-pilot-study-of-antibody-acquisition-in-recurrent-natural-infections
#8
Elise Schieck, E Jane Poole, Anja Rippert, Judy Peshu, Philip Sasi, Steffen Borrmann, Peter C Bull
BACKGROUND: During intra-erythrocytic replication Plasmodium falciparum escapes the human host immune system by switching expression of variant surface antigens (VSA). Piecemeal acquisition of variant specific antibody responses to these antigens as a result of exposure to multiple re-infections has been proposed to play a role in acquisition of naturally acquired immunity. METHODS: Immunofluorescence was used to explore the dynamics of anti-VSA IgG responses generated by children to (i) primary malaria episodes and (ii) recurrent P...
November 7, 2017: Malaria Journal
https://www.readbyqxmd.com/read/29096194/molecular-interactions-governing-host-specificity-of-blood-stage-malaria-parasites
#9
REVIEW
Erik J Scully, Usheer Kanjee, Manoj T Duraisingh
Non-human primates harbor diverse species of malaria parasites, including the progenitors of Plasmodium falciparum and Plasmodium vivax. Cross-species transmission of some malaria parasites-most notably the macaque parasite, Plasmodium knowlesi-continues to this day, compelling the scientific community to ask whether these zoonoses could impede malaria control efforts by acting as a source of recurrent human infection. Host-restriction varies considerably among parasite species and is governed by both ecological and molecular variables...
October 30, 2017: Current Opinion in Microbiology
https://www.readbyqxmd.com/read/29069339/is-placental-malaria-a-long-term-risk-factor-for-mild-malaria-attack-in-infancy-revisiting-a-paradigm
#10
Olivier Bouaziz, David Courtin, Gilles Cottrell, Jacqueline Milet, Gregory Nuel, André Garcia
Background: Children born to mothers with placental malaria (PM) have been described as more susceptible to the occurrence of a first malaria infection. However, whether or not these children remain more at risk during infancy has never been explored. We aimed to determine if children born to mothers with PM are more susceptible to malaria and remain at higher risk between birth and 18 months. Methods: 550 children were weekly followed-up with control of temperature and, if >37...
October 21, 2017: Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America
https://www.readbyqxmd.com/read/29065822/privileged-structures-in-the-design-of-potential-drug-candidates-for-neglected-diseases
#11
Ana Cristina Lima Leite, José Wanderlan Pontes Espíndola, Marcos Veríssimo de Oliveira Cardoso, Gevanio Bezerra de Oliveira Filho
Privileged motifs are recurring in a wide range of biologically active compounds that reach different pharmaceutical targets and pathways and could represent a suitable start point to access potential candidates in the neglected diseases field. The current therapies to treat these diseases are based in drugs that lack of the desired effectiveness, affordable methods of synthesis and allow a way to emergence of resistant strains. Due the lack of financial return, only few pharmaceutical companies have been investing in research for new therapeutics for neglected diseases (ND)...
October 23, 2017: Current Medicinal Chemistry
https://www.readbyqxmd.com/read/29029609/modelling-the-implications-of-stopping-vector-control-for-malaria-control-and-elimination
#12
Joshua O Yukich, Nakul Chitnis
BACKGROUND: Increasing coverage of malaria vector control interventions globally has led to significant reductions in disease burden. However due to its high recurrent cost, there is a need to determine if and when vector control can be safely scaled back after transmission has been reduced. METHODS AND FINDINGS: A mathematical model of Plasmodium falciparum malaria epidemiology was simulated to determine the impact of scaling back vector control on transmission and disease...
October 13, 2017: Malaria Journal
https://www.readbyqxmd.com/read/28975859/recrudescing-plasmodium-malariae-infection-despite-appropriate-treatment-in-an-immigrant-toddler
#13
Shamim Islam, Faizi Hai
Compared with other plasmodium species which cause human malaria, Plasmodium malariae is considered to be relatively infrequent and milder, although recent reports indicate that its prevalence and impact have been under-estimated. A 23-month-old boy, born and previously living in a refugee camp in Liberia who presented with P. malariae 6 weeks after arrival in the USA, is reported. Despite ostensibly effective anti-malarial treatment with artemether/lumefantrine and two courses of hydrochloroquine, he experienced recurrent parasitaemia, refractory anaemia and splenomegaly over a 6-month period; the symptoms resolved after he received atovaquone/proguanil...
October 4, 2017: Paediatrics and International Child Health
https://www.readbyqxmd.com/read/28934955/the-drug-transporter-abcb1-c-3435c-t-snp-influences-artemether-lumefantrine-treatment-outcome
#14
Kinanga Kiaco, António Sebastião Rodrigues, Virgílio do Rosário, José Pedro Gil, Dinora Lopes
Malaria treatment performance is potentially influenced by pharmacogenetic factors. This study reports an association study between the ABCB1 c.3435C>T, CYP3A4*1B (g.-392A>G), CYP3A5*3 (g.6986A>G) SNPs and artemether + lumefantrine treatment outcome in 103 uncomplicated malaria patients from Angola. No significant associations with the CYP3A4*1B and CYP3A5*3 were observed, while a significant predominance of the ABCB1 c.3435CC genotype was found among the recurrent infection-free patients (p < 0...
September 21, 2017: Malaria Journal
https://www.readbyqxmd.com/read/28916443/aq-13-an-investigational-antimalarial-versus-artemether-plus-lumefantrine-for-the-treatment-of-uncomplicated-plasmodium-falciparum-malaria-a-randomised-phase-2-non-inferiority-clinical-trial
#15
Ousmane A Koita, Lansana Sangaré, Haiyan D Miller, Aliou Sissako, Moctar Coulibaly, Trevor A Thompson, Saharé Fongoro, Youssouf Diarra, Mamadou Ba, Ababacar Maiga, Boubakar Diallo, David M Mushatt, Frances J Mather, Jeffrey G Shaffer, Asif H Anwar, Donald J Krogstad
BACKGROUND: Chloroquine was used for malaria treatment until resistant Plasmodium falciparum was identified. Because 4-aminoquinolines with modified side chains, such as AQ-13, are active against resistant parasites, we compared AQ-13 against artemether plus lumefantrine for treatment of uncomplicated P falciparum malaria. METHODS: We did a randomised, non-inferiority trial. We screened men (≥18 years) with uncomplicated malaria in Missira (northeast Mali) and Bamako (capital of Mali) for eligibility (≥2000 asexual P falciparum parasites per μL of blood)...
September 12, 2017: Lancet Infectious Diseases
https://www.readbyqxmd.com/read/28893687/genetic-analysis-of-id1-dbl2x-predicts-its-validity-as-a-vaccine-candidate-in-colombia-and-supports-at-least-two-independently-introduced-plasmodium-falciparum-populations-in-the-region
#16
J Rajwani, C M Klinger, E Arango, M I Arroyo, A Sabbagh, A Maestre, J B Dacks, S Gnidehou, S K Yanow
Pregnancy-associated malaria (PAM) poses a threat to both the mother and fetus, increasing the risk of severe maternal anemia, fetal growth restriction and low birth weight infants. Two vaccines are currently in development to protect women from Plasmodium falciparum in pregnancy. Both vaccine constructs target the ID1-DBL2X domain of VAR2CSA, a protein expressed on the surface of infected erythrocytes (IEs) that mediates parasite sequestration in the placenta. Although development of an effective vaccine may be hampered by ID1-DBL2X polymorphisms expressed by field isolates, a recent study showed that genetic variation of this domain in South American parasite populations is much lower than in other geographical locations...
September 8, 2017: Infection, Genetics and Evolution
https://www.readbyqxmd.com/read/28822205/comparison-of-effectiveness-of-two-different-artemisinin-based-combination-therapies-in-an-area-with-high-seasonal-transmission-of-malaria-in-burkina-faso
#17
Paul Sondo, Karim Derra, Seydou Diallo Nakanabo, Zekiba Tarnagda, Adama Kazienga, Innocent Valea, Herman Sorgho, Jean-Bosco Ouédraogo, Tinga Robert Guiguemdé, Halidou Tinto
In Sahelian countries such as Burkina Faso, malaria transmission is seasonal with a high incidence of transmission during the rainy season. This study aimed to compare the effectiveness of the two recommended treatments (Artemether-Lumefantrine and Artesunate-Amodiaquine) for uncomplicated malaria in Burkina Faso regarding this seasonal variation of malaria transmission. This is part of a randomized open label trial comparing the effectiveness and safety of Artemether-Lumefantrine versus Artesunate-Amodiaquine according to routine practice in Nanoro...
2017: Annals of Parasitology
https://www.readbyqxmd.com/read/28813452/plasma-metabolomics-reveals-membrane-lipids-aspartate-asparagine-and-nucleotide-metabolism-pathway-differences-associated-with-chloroquine-resistance-in-plasmodium-vivax-malaria
#18
Karan Uppal, Jorge L Salinas, Wuelton M Monteiro, Fernando Val, Regina J Cordy, Ken Liu, Gisely C Melo, Andre M Siqueira, Belisa Magalhaes, Mary R Galinski, Marcus V G Lacerda, Dean P Jones
BACKGROUND: Chloroquine (CQ) is the main anti-schizontocidal drug used in the treatment of uncomplicated malaria caused by Plasmodium vivax. Chloroquine resistant P. vivax (PvCR) malaria in the Western Pacific region, Asia and in the Americas indicates a need for biomarkers of resistance to improve therapy and enhance understanding of the mechanisms associated with PvCR. In this study, we compared plasma metabolic profiles of P. vivax malaria patients with PvCR and chloroquine sensitive parasites before treatment to identify potential molecular markers of chloroquine resistance...
2017: PloS One
https://www.readbyqxmd.com/read/28722611/phase-2a-open-label-4-escalating-dose-randomized-multicenter-study-evaluating-the-safety-and-activity-of-ferroquine-ssr97193-plus-artesunate-versus-amodiaquine-plus-artesunate-in-african-adult-men-with-uncomplicated-plasmodium-falciparum-malaria
#19
RANDOMIZED CONTROLLED TRIAL
Christian Supan, Ghyslain Mombo-Ngoma, Maryvonne Kombila, Carmen L Ospina Salazar, Jana Held, Bertrand Lell, Cathy Cantalloube, Elhadj Djeriou, Bernhards Ogutu, John Waitumbi, Nekoye Otsula, Duncan Apollo, Mark E Polhemus, Peter G Kremsner, Douglas S Walsh
Artemisinin-based combination therapies are recommended as first-line agents for treating uncomplicated Plasmodium falciparum malaria. Ferroquine, a 4-aminoquinolone, is a novel long-acting combination partner for fast-acting drugs like artesunate (AS). We did a small phase 2a, multicenter, open-label, safety-focused dose-ranging randomized study of ferroquine at three African hospitals: two Gabonese and one Kenyan. We recruited adult men with symptomatic uncomplicated P. falciparum monoinfection. Four escalating doses of ferroquine (100, 200, 400, and 600 mg) were assessed in sequence, versus an amodiaquine comparator...
August 2017: American Journal of Tropical Medicine and Hygiene
https://www.readbyqxmd.com/read/28645255/haemoglobin-changes-and-risk-of-anaemia-following-treatment-for-uncomplicated-falciparum-malaria-in-sub-saharan-africa
#20
Julien Zwang, Umberto D'Alessandro, Jean-Louis Ndiaye, Abdoulaye A Djimdé, Grant Dorsey, Andreas A Mårtensson, Corine Karema, Piero L Olliaro
BACKGROUND: Anaemia is common in malaria. It is important to quantitate the risk of anaemia and to distinguish factors related to the natural history of disease from potential drug toxicity. METHODS: Individual-patient data analysis based on nine randomized controlled trials of treatments of uncomplicated falciparum malaria from 13 sub-Saharan African countries. Risk factors for reduced haemoglobin (Hb) concentrations and anaemia on presentation and after treatment were analysed using mixed effect models...
June 23, 2017: BMC Infectious Diseases
keyword
keyword
65117
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"